Curis Initiates Patient Enrollment in TakeAim CLL Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: PRnewswire
- Clinical Trial Launch: Curis has opened patient enrollment at eleven clinical sites for its TakeAim CLL study, reflecting strong investigator interest in the combination of emavusertib and zanubrutinib for treating Chronic Lymphocytic Leukemia, which may enhance the company's market position in this therapeutic area.
- Patient Dosing Plan: The company reaffirmed its commitment to dosing the initial five patients by the end of July 2026, with preliminary data expected in December 2026, which will provide critical clinical insights that could influence future treatment protocols.
- Reverse Stock Split: At the special stockholder meeting on June 25, 2026, shareholders approved a reverse stock split proposal with a ratio ranging from 1-for-5 to 1-for-25, aimed at regaining compliance with Nasdaq's $1.00 bid price rule, demonstrating the company's commitment to shareholder interests.
- Funding Warning: Curis faces significant funding challenges and requires additional capital to support the development and operations of emavusertib; failure to secure sufficient funding could delay or reduce the scope of clinical trials, adversely impacting the company's future market performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRIS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRIS
Wall Street analysts forecast CRIS stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.206
Low
5.00
Averages
11.00
High
17.00
Current: 0.206
Low
5.00
Averages
11.00
High
17.00
About CRIS
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Curis Initiates Patient Enrollment in TakeAim CLL Study
- Clinical Trial Launch: Curis has opened patient enrollment at eleven clinical sites for its TakeAim CLL study, reflecting strong investigator interest in the combination of emavusertib and zanubrutinib for treating Chronic Lymphocytic Leukemia, which may enhance the company's market position in this therapeutic area.
- Patient Dosing Plan: The company reaffirmed its commitment to dosing the initial five patients by the end of July 2026, with preliminary data expected in December 2026, which will provide critical clinical insights that could influence future treatment protocols.
- Reverse Stock Split: At the special stockholder meeting on June 25, 2026, shareholders approved a reverse stock split proposal with a ratio ranging from 1-for-5 to 1-for-25, aimed at regaining compliance with Nasdaq's $1.00 bid price rule, demonstrating the company's commitment to shareholder interests.
- Funding Warning: Curis faces significant funding challenges and requires additional capital to support the development and operations of emavusertib; failure to secure sufficient funding could delay or reduce the scope of clinical trials, adversely impacting the company's future market performance.
See More
Curis Initiates CLL Study and Confirms Shareholder Vote Results
- Clinical Trial Launch: Curis announced that its TakeAim CLL study for Chronic Lymphocytic Leukemia is now open for patient enrollment at eleven clinical sites, reflecting strong investigator interest in the combination of emavusertib and zanubrutinib aimed at achieving dual blockade of NF-kB, a key driver of CLL.
- Patient Dosing Plan: The company reaffirmed its guidance to dose the initial five patients in the TakeAim CLL study by the end of July 2026, with preliminary data expected in December 2026, which will lay the groundwork for further clinical advancements.
- Shareholder Vote Results: At the special meeting on June 25, 2026, Curis shareholders approved a reverse stock split proposal with a ratio ranging from 1-for-5 to 1-for-25, aimed at regaining compliance with Nasdaq's $1.00 bid price rule, with the final ratio to be determined by the Board of Directors.
- Market Compliance: Curis emphasized that shareholder support will aid in regaining compliance with Nasdaq, with CEO James Dentzer highlighting operational progress in the CLL study and the potential for future successes, demonstrating the company's confidence in the market.
See More
Curis, Inc. Q1 2026 Earnings Call Insights
- Clinical Study Progress: Curis is making steady progress in its TakeAim study for primary CNS lymphoma, expecting to provide updated emavusertib clinical data in the first half of 2027, which will support accelerated submissions in the U.S. and Europe, indicating the company's strategic positioning in oncology treatment.
- Financial Loss Overview: Curis reported a net loss of $24.2 million or $1.25 per share for Q1 2026, significantly higher than the $10.6 million loss in the same period of 2025, primarily due to changes in the fair value of warrant liabilities associated with the January 2026 PIPE financing, reflecting pressure on the company's financing structure.
- R&D Expense Changes: Research and development expenses were $6.4 million in Q1, down from $8.5 million in the prior year, attributed mainly to lower employee-related and manufacturing costs, demonstrating the company's efforts in cost control.
- Funding Status and Outlook: As of March 31, 2026, Curis had cash and cash equivalents of $15 million, with anticipated gross proceeds of up to $20.2 million from the exercise of January 2026 PIPE financing warrants, which should enable operations into the second half of 2027, indicating a cautious approach to financial management.
See More
Curis Inc Reports Q1 2026 Earnings and Study Progress
- Study Progress: Curis Inc is making steady progress in its Teykain lymphoma study, anticipating accelerated submissions in the U.S. and Europe, which could enhance its market position in treating difficult NHL subtypes.
- Financial Performance: The company reported a net loss of $24.2 million for Q1 2026, a significant increase from the previous year, primarily due to changes in the fair value of warrant liabilities related to recent financing, potentially impacting future financing capabilities.
- Recruitment Challenges: Enrollment in the PCNSL study has been described as 'lumpy,' indicating potential challenges in patient recruitment that may affect the study's timeline and outcomes.
- Future Outlook: While not currently pursuing commercial partnerships for its AML program, Curis plans to leverage existing resources to advance its studies, with expectations to fully enroll the PCNSL study by 2027, reflecting a cautiously optimistic outlook for future growth.
See More
Curis Reports Q1 Earnings Miss with Strategic Cash Position
- Earnings Miss: Curis reported a Q1 GAAP EPS of -$1.25, missing expectations by $0.90, indicating challenges in profitability that could impact investor confidence and stock performance.
- Cash Position: As of March 31, 2026, Curis had $15.0 million in cash and cash equivalents, reflecting tight liquidity in the short term, necessitating careful management of operational expenditures to sustain business continuity.
- Financing Strategy: The company anticipates gross proceeds of up to $20.2 million from the exercise of January 2026 PIPE Financing Series B Warrants, which should support operations into the second half of 2027, particularly in clinical trial activities.
- Clinical Trial Goals: Curis aims for full enrollment in its PCNSL registrational study within 12-18 months while advancing its CLL proof-of-concept, which, if successful, could provide significant growth momentum for the company.
See More
Curis Reports Q1 2026 Business Update and Financial Results
- Clinical Trial Progress: Curis's emavusertib is undergoing a Phase 1/2 trial in the TakeAim Lymphoma study, aimed at treating relapsed or refractory primary CNS lymphoma in combination with ibrutinib, with orphan drug designation granted by both the FDA and EMA to support accelerated approval filings.
- Financial Performance: For the quarter ended March 31, 2026, Curis reported a net loss of $24.2 million, or $1.25 per share, an increase from a net loss of $10.6 million in the same quarter of 2025, primarily due to rising R&D and administrative expenses, with no revenues recorded this quarter.
- Funding Initiatives: Curis completed a private placement in January 2026, expected to yield up to $80.8 million in gross proceeds, including approximately $20.2 million in initial proceeds, which will be used to support future clinical trials and operations.
- Upcoming Milestones: Curis anticipates announcing the dosing of the first five patients in the TakeAim CLL study by mid-2026, with data expected in December 2026, showcasing its potential in chronic lymphocytic leukemia treatment.
See More
Curis Initiates Patient Enrollment in TakeAim CLL Study
- Clinical Trial Launch: Curis has opened patient enrollment at eleven clinical sites for its TakeAim CLL study, reflecting strong investigator interest in the combination of emavusertib and zanubrutinib for treating Chronic Lymphocytic Leukemia, which may enhance the company's market position in this therapeutic area.
- Patient Dosing Plan: The company reaffirmed its commitment to dosing the initial five patients by the end of July 2026, with preliminary data expected in December 2026, which will provide critical clinical insights that could influence future treatment protocols.
- Reverse Stock Split: At the special stockholder meeting on June 25, 2026, shareholders approved a reverse stock split proposal with a ratio ranging from 1-for-5 to 1-for-25, aimed at regaining compliance with Nasdaq's $1.00 bid price rule, demonstrating the company's commitment to shareholder interests.
- Funding Warning: Curis faces significant funding challenges and requires additional capital to support the development and operations of emavusertib; failure to secure sufficient funding could delay or reduce the scope of clinical trials, adversely impacting the company's future market performance.
See More
Curis Initiates CLL Study and Confirms Shareholder Vote Results
- Clinical Trial Launch: Curis announced that its TakeAim CLL study for Chronic Lymphocytic Leukemia is now open for patient enrollment at eleven clinical sites, reflecting strong investigator interest in the combination of emavusertib and zanubrutinib aimed at achieving dual blockade of NF-kB, a key driver of CLL.
- Patient Dosing Plan: The company reaffirmed its guidance to dose the initial five patients in the TakeAim CLL study by the end of July 2026, with preliminary data expected in December 2026, which will lay the groundwork for further clinical advancements.
- Shareholder Vote Results: At the special meeting on June 25, 2026, Curis shareholders approved a reverse stock split proposal with a ratio ranging from 1-for-5 to 1-for-25, aimed at regaining compliance with Nasdaq's $1.00 bid price rule, with the final ratio to be determined by the Board of Directors.
- Market Compliance: Curis emphasized that shareholder support will aid in regaining compliance with Nasdaq, with CEO James Dentzer highlighting operational progress in the CLL study and the potential for future successes, demonstrating the company's confidence in the market.
See More
Curis, Inc. Q1 2026 Earnings Call Insights
- Clinical Study Progress: Curis is making steady progress in its TakeAim study for primary CNS lymphoma, expecting to provide updated emavusertib clinical data in the first half of 2027, which will support accelerated submissions in the U.S. and Europe, indicating the company's strategic positioning in oncology treatment.
- Financial Loss Overview: Curis reported a net loss of $24.2 million or $1.25 per share for Q1 2026, significantly higher than the $10.6 million loss in the same period of 2025, primarily due to changes in the fair value of warrant liabilities associated with the January 2026 PIPE financing, reflecting pressure on the company's financing structure.
- R&D Expense Changes: Research and development expenses were $6.4 million in Q1, down from $8.5 million in the prior year, attributed mainly to lower employee-related and manufacturing costs, demonstrating the company's efforts in cost control.
- Funding Status and Outlook: As of March 31, 2026, Curis had cash and cash equivalents of $15 million, with anticipated gross proceeds of up to $20.2 million from the exercise of January 2026 PIPE financing warrants, which should enable operations into the second half of 2027, indicating a cautious approach to financial management.
See More
Curis Inc Reports Q1 2026 Earnings and Study Progress
- Study Progress: Curis Inc is making steady progress in its Teykain lymphoma study, anticipating accelerated submissions in the U.S. and Europe, which could enhance its market position in treating difficult NHL subtypes.
- Financial Performance: The company reported a net loss of $24.2 million for Q1 2026, a significant increase from the previous year, primarily due to changes in the fair value of warrant liabilities related to recent financing, potentially impacting future financing capabilities.
- Recruitment Challenges: Enrollment in the PCNSL study has been described as 'lumpy,' indicating potential challenges in patient recruitment that may affect the study's timeline and outcomes.
- Future Outlook: While not currently pursuing commercial partnerships for its AML program, Curis plans to leverage existing resources to advance its studies, with expectations to fully enroll the PCNSL study by 2027, reflecting a cautiously optimistic outlook for future growth.
See More
Curis Reports Q1 Earnings Miss with Strategic Cash Position
- Earnings Miss: Curis reported a Q1 GAAP EPS of -$1.25, missing expectations by $0.90, indicating challenges in profitability that could impact investor confidence and stock performance.
- Cash Position: As of March 31, 2026, Curis had $15.0 million in cash and cash equivalents, reflecting tight liquidity in the short term, necessitating careful management of operational expenditures to sustain business continuity.
- Financing Strategy: The company anticipates gross proceeds of up to $20.2 million from the exercise of January 2026 PIPE Financing Series B Warrants, which should support operations into the second half of 2027, particularly in clinical trial activities.
- Clinical Trial Goals: Curis aims for full enrollment in its PCNSL registrational study within 12-18 months while advancing its CLL proof-of-concept, which, if successful, could provide significant growth momentum for the company.
See More
Curis Reports Q1 2026 Business Update and Financial Results
- Clinical Trial Progress: Curis's emavusertib is undergoing a Phase 1/2 trial in the TakeAim Lymphoma study, aimed at treating relapsed or refractory primary CNS lymphoma in combination with ibrutinib, with orphan drug designation granted by both the FDA and EMA to support accelerated approval filings.
- Financial Performance: For the quarter ended March 31, 2026, Curis reported a net loss of $24.2 million, or $1.25 per share, an increase from a net loss of $10.6 million in the same quarter of 2025, primarily due to rising R&D and administrative expenses, with no revenues recorded this quarter.
- Funding Initiatives: Curis completed a private placement in January 2026, expected to yield up to $80.8 million in gross proceeds, including approximately $20.2 million in initial proceeds, which will be used to support future clinical trials and operations.
- Upcoming Milestones: Curis anticipates announcing the dosing of the first five patients in the TakeAim CLL study by mid-2026, with data expected in December 2026, showcasing its potential in chronic lymphocytic leukemia treatment.
See More
